Ken Kato

90PUBLICATIONS
257CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEpidemiological methodsSocial epidemiologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (90)

|Oct 05, 2026
First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306).

|Sep 17, 2026
Prognostic Impact of Serum microRNA Profiles on the Progression-Free Survival of Patients With High-Grade Serous Ovarian Cancer Receiving Neoadjuvant Chemotherapy.

|Sep 16, 2026
Metastasis-directed local therapy and strategic de-escalation of systemic therapy for oligometastatic esophageal squamous cell carcinoma.

|Aug 27, 2026
Institutional enrollment volume and clinical outcomes after surgery or chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma: a supplementary analysis of JCOG0502.

|Aug 03, 2026
Oligometastatic esophageal squamous cell carcinoma: a systematic review of current definitions and meta-analysis of local therapy outcomes.

|Jul 20, 2026
Real-world treatments and outcomes in metastatic and recurrent esophageal squamous cell carcinoma in Japan: a retrospective analysis using the Millennial Medical Record database.

Pageof 15

Frequent Collaborators

12 joint publications

Takayuki Yoshino

10 joint publications

Hideaki Bando

7 joint publications

Eiji Oki

7 joint publications

Yoshito Komatsu